A study recently has proved that stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscles and reversed scarring one year later, the authors say.
USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer’s disease.
Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal.
A new study has been found by The University of Texas Health Science Center at San Antonio that Bat plant, or Tacca chantrieri, could be used to fight cancer.
Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
Scientist have again achieved a great success by developing a new drug KG5, which kills off cancer and also could wipe out some of the most deadly forms of the disease. It also acts by cutting off the blood supply to tumours.This drug is expected to hit the market in 5years.
Malaria has been a serious issue since a long period of time and controlling malaria has been a top goal of international public-health authorities. Caused by parasites transmitted by infected mosquitoes, malaria annually sickens more than 200 million people and kills nearly 800,000, mostly children in Africa. Because children are the most vulnerable to the disease, efforts to develop a vaccine have focused on them.
Israel based pharmaceutical company Teva, the world's biggest generic drug maker, will reportedly be able to exclusively distribute its version of the Lipitor cholesterol-lowering medicine due to its collaboration with Indian pharmaceutical company Ranbaxy, which holds a 180-day permit to distribute the generic drug, Calcalist , it is learned.
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
If a shareholder had invested about Rs 2,500 in Dr Reddy's Laboratories through the IPO in August 1986 and the rights issue of 1989, what do you think the holding would be worth today? A whopping Rs 40 lakh!
In this arena, we believe there should be two broad priorities for India. First, to ensure that there is timely access to affordable quality medicine for the underprivileged. Second, due to the global scale and impact of the Indian pharmaceutical industry, to ensure that we give it the most comprehensive support that it deserves.
Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.
Surging growth and global operations ensure they can’t be family-run any longer.
After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.
Indian drugmakers could see excise duty on drugs restored to 8 percent from the present 4 percent, but they are hopeful research & development could attract some tax sops in the Union budget on Feb. 26.
The entry of global pharma firms in the generic market will put strain on Indian drug companies, which will have to manage costs and maintain profitability to be able to compete with them, says credit rating agency Fitch.
In a recent reversal, operations abroad are hampering profit.
Catalyz is developing affordable diagnostic and care systems for infectious and chronic diseases. The tests need no technical knowledge or any device to interpret the result, hence making it easy for a lame man in confirming or ruling out certain diseases.
In an ambitious move to boost drug discovery, the Centre plans to create a fund of Rs 2,000-3,000 crore for pharma research and development, a top government official said here today.
Pfizer India and Arpana Research and Charities Trust announced today the expansion of their existing grassroots initiatives aimed at strengthening the healthcare system to cover 100 low-income villages in Haryana by 2012. They also announced the launch of a joint project with USAID and CAP Foundation aimed at employment generation for rural youth.